Practical Geriatrics ›› 2023, Vol. 37 ›› Issue (11): 1176-1180.doi: 10.3969/j.issn.1003-9198.2023.11.024
Previous Articles Next Articles
Received:2023-01-28
Online:2023-11-20
Published:2023-11-22
CLC Number:
| [1] OWONIKOKO T K, RAGIN C C, BELANI C P, et al. Lung cancer in elderly patients:an analysis of the surveillance, epidemiology, and end results database[J]. J Clin Oncol, 2007, 25(35): 5570-5577. [2] DE GROOT P M, WU C C, CARTER B W, et al. The epidemiology of lung cancer[J]. Transl Lung Cancer Res, 2018, 7(3): 220-233. [3] SEZER A, KILICKAP S, GÜMÜŞ M, et al. Cemiplimab monotherapy for first-line treatment of advanced non-small-cell lung cancer with PD-L1 of at least 50%:a multicentre, open-label, global, phase 3, randomised, controlled trial[J]. Lancet, 2021, 397(10274): 592-604. [4] HORN L, SPIGEL D R, VOKES E E, et al. Nivolumab versus docetaxel in previously treated patients with advanced non-small-cell lung cancer: two-year outcomes from two randomized, open-label, phase Ⅲ trials (CheckMate 017 and CheckMate 057)[J]. J Clin Oncol, 2017, 35(35): 3924-3933. [5] HERBST R S, GIACCONE G, DE MARINIS F, et al. Atezolizumab for first-line treatment of PD-L1-selected patients with NSCLC[J]. N Engl J Med, 2020, 383(14): 1328-1339. [6] HERBST R S, BAAS P, KIM D W, et al. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010):a randomised controlled trial[J]. Lancet, 2016, 387(10027): 1540-1550. [7] MAGEE D E, HIRD A E, KLAASSEN Z, et al. Adverse event profile for immunotherapy agents compared with chemotherapy in solid organ tumors:a systematic review and meta-analysis of randomized clinical trials[J]. Ann Oncol, 2020, 31(1): 50-60. [8] VINAY D S, RYAN E P, PAWELEC G, et al. Immune evasion in cancer: Mechanistic basis and therapeutic strategies[J]. Semin Cancer Biol, 2015, 35(Suppl): S185-S198. [9] FERRARA R, NAIGEON M, AUCLIN E, et al. Circulating T-cell immunosenescence in patients with advanced non-small cell lung cancer treated with single-agent PD-1/PD-L1 inhibitors or platinum-based chemotherapy[J]. Clin Cancer Res, 2021, 27(2): 492-503. [10] FRASCA D, DIAZ A, ROMERO M, et al. B cell immunosenescence[J]. Annu Rev Cell Dev Biol, 2020, 36: 551-574. [11] BALDINI C, MARTIN ROMANO P, VOISIN A L, et al. Impact of aging on immune-related adverse events generated by anti-programmed death (ligand)PD-(L)1 therapies[J]. Eur J Cancer, 2020, 129: 71-79. [12] HELLMANN M D, CIULEANU T E, PLUZANSKI A, et al. Nivolumab plus ipilimumab in lung cancer with a high tumor mutational burden[J]. N Engl J Med, 2018, 378(22): 2093-2104. [13] WHERRY E J, KURACHI M. Molecular and cellular insights into T cell exhaustion[J]. Nat Rev Immunol, 2015, 15(8): 486-499. [14] BORGHAEI H, PAZ-ARES L, HORN L, et al. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer[J]. N Engl J Med, 2015, 373(17): 1627-1639. [15] RITTMEYER A, BARLESI F, WATERKAMP D, et al. Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (oak): a phase 3, open-label, multicentre randomised controlled trial[J]. Lancet, 2017, 389(10066): 255-265. [16] RECK M, RODRíGUEZ-ABREU D, ROBINSON A G, et al. Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer[J]. N Engl J Med, 2016, 375(19): 1823-1833. [17] CHAMPIAT S, DERCLE L, AMMARI S, et al. Hyperprogressive disease is a new pattern of progression in cancer patients treated by anti-PD-1/PD-L1[J]. Clin Cancer Res, 2017, 23(8): 1920-1928. [18] PAZ-ARES L, LUFT A, VICENTE D, et al. Pembrolizumab plus chemotherapy for squamous non-small-cell lung cancer[J]. N Engl J Med, 2018, 379(21): 2040-2051. [19] GADGEEL S, RODRÍGUEZ-ABREU D, SPERANZA G, et al. Updated analysis from KEYNOTE-189: pembrolizumab or placebo plus pemetrexed and platinum for previously untreated metastatic nonsquamous non-small-cell lung cancer[J]. J Clin Oncol, 2020, 38(14): 1505-1517. [20] RECK M, MOK T S K, NISHIO M, et al. Atezolizumab plus bevacizumab and chemotherapy in non-small-cell lung cancer (IMpower150): key subgroup analyses of patients with egfr mutations or baseline liver metastases in a randomised, open-label phase 3 trial[J]. Lancet Respir Med, 2019, 7(5): 387-401. [21] WEST H, MCCLEOD M, HUSSEIN M, et al. Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trial[J]. Lancet Oncol, 2019, 20(7): 924-937. [22] SGAMBATO A, CASALUCE F, GRIDELLI C. The role of checkpoint inhibitors immunotherapy in advanced non-small cell lung cancer in the elderly[J]. Expert Opin Biol Ther, 2017, 17(5): 565-571. [23] PAZ-ARES L, CIULEANU T E, COBO M, et al. First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in patients with non-small-cell lung cancer (CheckMate 9LA): an international, randomised, open-label, phase 3 trial[J]. Lancet Oncol, 2021, 22(2): 198-211. [24] REN S, XIONG X, YOU H, et al. The combination of immune checkpoint blockade and angiogenesis inhibitors in the treatment of advanced non-small cell lung cancer[J]. Front Immunol, 2021, 12: 689132. [25] RECKAMP K L, REDMAN M W, DRAGNEV K H, et al. Phase II randomized study of ramucirumab and pembrolizumab versus standard of care in advanced non-small-cell lung cancer previously treated with immunotherapy-lung-map s1800a[J]. J Clin Oncol, 2022, 40(21): 2295-2306. [26] LV W, PEI X, ZHAO W, et al. Safety and efficacy of nivolumab plus recombinant human endostatin in previously treated advanced non-small-cell lung cancer[J]. Transl Lung Cancer Res, 2022, 11(2): 201-212. [27] ALEXA T, ANTONIU S A, ALEXA I, et al. Checkpoint inhibitors in NSCLC for the elderly: current challenges and perspectives[J]. Expert Rev Anticancer Ther, 2021, 21(3): 315-323. [28] LICHTENSTEIN M R L, NIPP R D, MUZIKANSKY A, et al. Impact of age on outcomes with immunotherapy in patients with non-small cell lung cancer[J]. J Thorac Oncol, 2019, 14(3): 547-552. [29] RODRÍGUEZ-ABREU D, POWELL S F, HOCHMAIR M J, et al. Pemetrexed plus platinum with or without pembrolizumab in patients with previously untreated metastatic nonsquamous nsclc: protocol-specified final analysis from KEYNOTE-189[J]. Ann Oncol, 2021, 32(7): 881-895. [30] MUCHNIK E, LOH K P, STRAWDERMAN M, et al. Immune checkpoint inhibitors in real-world treatment of older adults with non-small cell lung cancer[J]. J Am Geriatr Soc, 2019, 67(5): 905-912. [31] GOMES F, LORIGAN P, WOOLLEY S, et al. A prospective cohort study on the safety of checkpoint inhibitors in older cancer patients-the elders study[J]. ESMO Open, 2021, 6(1): 100042. [32] GARCIA M V, AGAR M R, SOO W K, et al. Screening tools for identifying older adults with cancer who may benefit from a geriatric assessment: a systematic review[J]. JAMA Oncol, 2021, 7(4): 616-627. [33] MORAD G, HELMINK B A, SHARMA P, et al. Hallmarks of response, resistance, and toxicity to immune checkpoint blockade[J]. Cell, 2021, 184(21): 5309-5337. [34] ALPERT A, PICKMAN Y, LEIPOLD M, et al. A clinically meaningful metric of immune age derived from high-dimensional longitudinal monitoring[J]. Nat Med, 2019, 25(3): 487-495. |
| [1] | . [J]. Practical Geriatrics, 2024, 38(5): 509-437. |
| [2] | . [J]. Practical Geriatrics, 2024, 38(2): 205-209. |
| [3] | WANG Tian, YE Jin-jun, LI Hui, SHI Shu-tong, ZHANG Zhi, ZHOU Guo-ren, WANG Qiang, ZHANG Rong-rong, HE Xia. Correlation of NLR and PLR before immune consolidation therapy with prognosis in elderly patients with stage Ⅲ non-small cell lung cancer [J]. Practical Geriatrics, 2023, 37(11): 1120-1124. |
| [4] | YUAN Yi-dan, LIU Zeng, LU Xi-hua. Effect of glycopyrrolate on pulmonary function and pulmonary shunt in elderly patients with lung cancer undergoing radical resection [J]. Practical Geriatrics, 2023, 37(7): 662-666. |
| [5] | . [J]. Practical Geriatrics, 2023, 37(4): 422-423. |
| Viewed | ||||||
|
Full text |
|
|||||
|
Abstract |
|
|||||
|
